Ebru Demet Aygit, Çigdem Altan, Hülya Güngel (Istanbul, Turkey)

Advantages:

This study reports clinical outcomes of intravitreal Ranibizumab treatment for choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) and to identify predictive factors that may influence visual acuity (VA) outcomes.

Methods:

Thirty-one patients (32 eyes) with CNV were followed up at least 6 months after intravitreal injection (0,5 mg) of Ranibizumab at baseline and subsequent injections on an as-needed basis. The VA outcomes were compared with baseline VA and evaluated across subgroups based on sex, age, baseline VA, injection number, CNV type, subfoveal cyst, epiretinal membrane, presence of systemic disease and prior photodynamic therapy.

Effectiveness / Safety:

The mean number injections were 4,2 ± 1,9 of cases. Photodynamic therapy in combination with Ranibizumab was applied 9 patients. VA improved or remained stable in 20 of 32 eyes (62.5%). Subgroup analysis showed that baseline VA influenced VA outcomes after Ranibizumab treatment (p= 0,001). However, the patients sex, baseline age, CNV type, subfoveal cyst, epiretinal membrane, presence of systemic disease and prior photodynamic therapy did not affect VA outcomes (p>0,05).

Take home message:

Intravitreal injections of Ranibizumab were shown to have improving and remaining effect on VA of patients with CNV secondary to AMD. Initial OCT findings did not influence VA results. Baseline VA was a predictive factor of VA outcomes after Ranibizumab treatment.